Adding Palbociclib to Maintenance Therapy Extends Time Without Progression in Advanced HER2-Positive, Hormone-Receptor–Positive Breast Cancer

Table of Contents

• Key Points
• Background: Why This Research Matters
• How the Study Was Designed
• Who Could Join the Trial
• The Treatment Plan and Dosing
• What Researchers Measured
• Statistical Plan: How Big and How Certain
• Results: The Patients Who Enrolled
• Key Findings: How Well the Treatment Worked
• Key Findings: Side Effects
• Clinical Implications: What This Means for Patients
• Limitations: What the Study Could Not Prove
• Recommendations and Practical Advice
• Frequently Asked Questions
• Source Information

Key Points

• In a phase 3 trial of 518 patients with hormone-receptor–positive, HER2-positive advanced breast cancer, adding palbociclib to maintenance therapy extended median progression-free survival from 29.1 to 44.3 months.
• The risk of cancer progression or death was 25% lower with palbociclib (hazard ratio 0.75), a statistically significant difference, but overall survival data are not yet mature.
• Severe neutropenia occurred in 55.9% of patients on palbociclib versus 2.0% on standard therapy, and 57.7% of patients needed a dose reduction.
• Eligible patients had completed four to eight cycles of trastuzumab-based induction chemotherapy without progression and started trial therapy within 12 weeks of the last infusion.
• The trial was open-label and subgroup analyses were underpowered, so it cannot determine which specific patient groups benefit most from adding palbociclib.

Background: Why This Research Matters

About one in five breast cancers makes too much of a protein called human epidermal growth factor receptor 2 (HER2). Doctors call these "HER2-positive." Researchers have spent decades developing drugs that block HER2, and those drugs have transformed outcomes for patients.

More than 50% of HER2-positive breast cancers also carry estrogen receptors, progesterone receptors, or both. These are the "hormone receptors." When a tumor has both HER2 and hormone receptors, it is a biologically distinct subgroup that behaves differently from tumors with only one of these features.

The current standard first-line treatment for hormone-receptor–positive, HER2-positive metastatic breast cancer (cancer that has spread beyond the breast) runs in two phases. First comes induction chemotherapy (chemo given to shrink the cancer quickly) combined with two HER2-blocking drugs — trastuzumab and pertuzumab — for several cycles. After that comes maintenance therapy: continued dual HER2 blockade plus endocrine therapy (hormone-blocking treatment).

But there is a problem. Laboratory studies show that the HER2 pathway and the estrogen-receptor pathway talk to each other. This "crosstalk" can help tumors resist treatment when doctors block only one pathway. Researchers have also identified a third driver: the axis formed by cyclin D1 and cyclin-dependent kinases 4 and 6 (CDK4/6) — proteins that control how fast cells divide. This machinery appears to drive tumor start-up, growth, and survival in HER2-positive breast cancer. It also appears to contribute to resistance against both endocrine therapy and HER2-targeted therapy.

That evidence gave researchers a clear hypothesis. Blocking HER2, the estrogen receptor, and the cell-division machinery all at once might improve disease control and possibly longer survival. Earlier-phase studies had already shown that combining a CDK4/6 inhibitor with both HER2-targeted and endocrine therapies was feasible and safe, and it might add benefit. So the research team tested palbociclib — a selective inhibitor of CDK4 and CDK6 — during the maintenance phase of treatment.

How the Study Was Designed

The trial was called PATINA (Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer). It was a phase 3 trial, meaning the final and largest stage of testing before a treatment is considered for routine use. It ran at 123 sites across eight countries.

PATINA was "open-label," which means patients and their doctors both knew which treatment each patient received. It was also randomized, so patients were assigned to groups by chance rather than by doctor choice. Researchers randomly assigned patients in a 1:1 ratio. One group received maintenance anti-HER2 and endocrine therapies plus palbociclib (the palbociclib group). The other received the same therapies without palbociclib (the standard-therapy group).

The trial was funded by Pfizer, which supplied the palbociclib used in the study, along with an academic collaboration led by Alliance Foundation Trials. Partner groups included Breast Cancer Trials (Australia and New Zealand), Fondazione Michelangelo, GBG Forschungs, PrECOG Cancer Research Group, SOLTI Breast Cancer Research Group, and Unicancer.

A multinational steering committee oversaw the trial, and that committee included Pfizer representatives. An independent data and safety monitoring board at the Alliance reviewed the efficacy and safety data. The trial followed Good Clinical Practice guidelines from the International Council for Harmonisation and the principles of the Declaration of Helsinki. Every patient gave written informed consent, and each site's institutional review board or ethics committee approved the protocol.

Who Could Join the Trial

Eligible patients were women or men aged 18 years or older with histologically confirmed (proven by tissue examination) hormone-receptor–positive and HER2-positive advanced breast cancer. The hormone receptor could be either the estrogen receptor or the progesterone receptor.

Hormone-receptor positivity was defined as at least 1% tumor-cell nuclear staining on immunohistochemical (IHC) analysis — a lab technique that uses antibodies to detect specific proteins in tissue. HER2 positivity was defined as an IHC score of 3+ or gene amplification detected by in situ hybridization, following guidelines from the American Society of Clinical Oncology and the College of American Pathologists.

Patients also had to meet specific treatment-history rules:

• They had completed a minimum of four and a maximum of eight cycles of trastuzumab-based induction chemotherapy, with no sign that the cancer had worsened. That meant achieving a complete response (cancer no longer detectable), a partial response (cancer shrank), or stable disease (cancer did not grow or shrink), as assessed at their own treatment center.
• Induction therapy included trastuzumab and pertuzumab plus a taxane (a type of chemotherapy). Single-agent HER2 blockade with trastuzumab alone was allowed in up to 20% of patients; for those patients, the chemotherapy backbone could be either a taxane or vinorelbine.
• No more than 12 weeks could pass between the last induction infusion and the first dose of the assigned trial therapy.
• Patients needed a disease-free interval of at least 6 months after any previous neoadjuvant (before surgery) or adjuvant (after surgery) anti-HER2 therapy up until the diagnosis of metastatic disease.
• They could have received no previous systemic therapy for metastatic disease other than their induction therapy.

Patients with asymptomatic central nervous system (CNS, meaning brain or spinal cord) metastases at diagnosis were eligible. If they had received prior CNS radiotherapy, at least 3 weeks had to pass between finishing radiation and day 1 of cycle 1, and they could not still need glucocorticoid (steroid) therapy.

Endocrine therapy in the trial was either an aromatase inhibitor or fulvestrant. Premenopausal patients were required to receive ovarian suppression — treatment that shuts down ovarian hormone production.

Randomization was stratified, meaning patients were sorted into balanced subgroups based on four factors: their response to induction therapy (complete or partial response versus stable disease), whether they had received previous neoadjuvant or adjuvant anti-HER2 therapy (yes or no), the type of endocrine therapy they received (aromatase inhibitor or fulvestrant), and whether they received single or dual HER2 blockade (trastuzumab alone, or trastuzumab plus pertuzumab).

The Treatment Plan and Dosing

Palbociclib was given as a pill by mouth at a dose of 125 mg daily for 21 days, followed by 7 days off, in repeating 28-day cycles. Dose reductions to 100 mg and then 75 mg were permitted if needed, consistent with the drug's approved labeling. If a patient needed a reduction below 75 mg, palbociclib was stopped permanently.

Complete blood counts (a blood test measuring different cell types) were checked at baseline, on day 1 of cycles 1 through 4, and every 3 months afterward. Patients in the palbociclib group had an extra blood count on day 22 of cycle 1.

Anti-HER2 and endocrine therapies were given according to standard guidelines, including subcutaneous (under-the-skin) formulations of trastuzumab and pertuzumab where available. Patients who stopped one component of therapy for safety reasons could keep receiving the remaining drugs. Importantly, growth factor support — medications that boost white blood cell production — was not allowed during the trial.

What Researchers Measured

The primary end point (the main result the trial was designed to answer) was investigator-assessed progression-free survival. This was defined as the time from randomization until documented disease progression or death from any cause, whichever happened first. Patients who had not progressed and had not died by the data cutoff were censored at the date of their last tumor assessment — meaning their data counted up to that point.

Secondary end points included:

• Confirmed objective response — measured from randomization and defined as a complete or partial response sustained for at least two consecutive assessments
• Overall survival — how long patients lived
• Safety — side effects and their severity

Tumor assessments used Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. These scans happened at baseline (within 28 days before randomization) and every 12 weeks afterward, continuing until disease progression, unacceptable toxic effects, withdrawal of consent, or death. Brain imaging was not required for patients without symptoms. Adverse events were recorded until 42 days after the final dose of a trial therapy and were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Researchers also tracked clinical benefit, which reflects patients who responded or had stable disease for a meaningful period.

Statistical Plan: How Big and How Certain

The trial was powered to detect a hazard ratio of 0.667 for investigator-assessed progression-free survival. A hazard ratio compares risk between groups; a value of 0.667 would mean the palbociclib group faced about one-third less risk of progression or death at any given time. This calculation assumed a median progression-free survival of 13.0 months in the standard-therapy group and 19.5 months in the palbociclib group.

Investigators calculated that 269 events (disease progression or death) were needed to give the study 90% power with a one-sided log-rank test at an alpha level of 0.025. "Power" describes the chance of detecting a real difference if one exists. The alpha level is the accepted risk of a false-positive result.

Two interim analyses were planned: a futility analysis after 135 events (about 50% of the target), and an efficacy analysis after 175 events (about 65%). Futility analysis asks whether the trial should stop early because the treatment clearly is not working. The sample size was also estimated to provide 80% power to detect an overall survival benefit extending survival from 50 months to 71.4 months (hazard ratio, 0.70) with a one-sided alpha level of 0.025.

Overall survival would be tested hierarchically at a strict one-sided alpha level of 0.0002 if progression-free survival reached significance at the interim or final analysis. Otherwise, the final overall survival analysis would be performed after 247 deaths occurred.

Interim analyses for progression-free survival took place in July 2021 (for futility) and December 2021 (for efficacy). The final progression-free survival analysis was conducted in October 2024, when 262 of the required 269 events had occurred. This decision rested on mature follow-up data (median, 53.5 months), continued treatment in 131 patients, and a plateauing event rate — roughly one progression or death event per month from October 2023 to October 2024. Based on the primary and sensitivity analyses, the data and safety monitoring board recommended releasing the trial data.

Efficacy analyses included all randomized patients. Safety analyses included the safety population — all patients who received at least one dose of a protocol-assigned therapy. Primary analyses used unstratified models and were confirmed with stratified models. Two-sided P values are reported for all end points. No statistical adjustments for multiple comparisons were planned for secondary end points, so those confidence intervals should not be used in place of formal hypothesis testing. All analyses used SAS version 9.4 and R version 4.4.1, with a data cutoff of October 14, 2024.

Results: The Patients Who Enrolled

From June 2017 through July 2021, a total of 518 patients enrolled and were randomly assigned: 261 to palbociclib plus anti-HER2 and endocrine therapies, and 257 to anti-HER2 and endocrine therapies alone.

About 10% of screened patients were deemed ineligible for various reasons, including disease progression after previous induction therapy — though the exact number due to progression was not recorded. Baseline characteristics were well balanced between the two groups.

The median age was 53.4 years, with a range from 28.7 to 84.3 years. Almost all patients — 99.4% — were female, and 61.8% were postmenopausal. Most patients were White (77.4% of those with data; 15.6% had missing race data). Black patients were both underrepresented and unevenly assigned between groups: 4 patients (1.5%) in the palbociclib group and 11 patients (4.3%) in the standard-therapy group.

Geographically, 32.0% of patients came from North America and 68.0% from Western Europe, Australia, or New Zealand. Performance status — a measure of how well patients carry out daily activities — was 0 (fully active) in 56.8% and 1 (restricted in strenuous activity but able to do light work) in 42.7%.

Regarding tumor characteristics:

• 97.5% were estrogen-receptor positive and 69.3% were progesterone-receptor positive
• 74.1% had an IHC HER2 score of 3+, and 25.1% had a score of 2+ with gene amplification
• 73.2% had visceral metastases (cancer in organs such as the liver or lungs), 22.6% had nonvisceral metastases, and 3.9% had central nervous system metastases

A total of 54.4% of patients had de novo metastatic disease. Researchers defined this as metastatic disease in a patient who had received no previous anti-HER2 therapy and who enrolled within 1 year after the diagnosis of the primary breast cancer.

The median number of induction therapy cycles before randomization was six. Overall, 70.1% of patients had a complete or partial response, and 29.3% had stable disease at the end of induction. The majority — 94.0% — received dual anti-HER2 therapy, and 90.7% received an aromatase inhibitor. Of the 29 patients (5.6%) treated with trastuzumab without pertuzumab, only 2 received vinorelbine rather than a taxane during induction.

At the end of the trial, 75 patients (28.7%) in the palbociclib group and 56 (21.8%) in the standard-therapy group were still receiving trial therapy. The most common reason for stopping treatment was disease progression: 124 patients (47.5%) in the palbociclib group and 136 patients (52.9%) in the standard-therapy group.

Key Findings: How Well the Treatment Worked

At a median follow-up of 53.5 months, the palbociclib group had significantly longer progression-free survival. Median progression-free survival was 44.3 months (95% confidence interval [CI], 32.4 to 56.8) in the palbociclib group versus 29.1 months (95% CI, 23.3 to 38.6) in the standard-therapy group. The hazard ratio for disease progression or death was 0.75 (95% CI, 0.59 to 0.96).

The statistical result was significant: two-sided unstratified P=0.02, and stratified P=0.03. In plain terms, a P value of 0.02 means there is about a 2% probability that a difference this large would appear by chance alone if the drug truly had no effect. This is below the trial's prespecified threshold for statistical significance.

Estimated progression-free survival at fixed time points strongly favored the palbociclib group:

• At 12 months: 84.9% with palbociclib versus 73.2% with standard therapy
• At 24 months: 65.2% versus 55.3%
• At 48 months: 46.5% versus 38.3%

Subgroup analyses were underpowered — meaning the trial did not enroll enough patients in each subgroup to draw firm conclusions about who benefits most. Those data are reported but should be interpreted cautiously.

The confirmed response rate (complete or partial response sustained for at least two consecutive assessments, excluding patients who had already achieved a complete response to induction treatment) was 32.9% (95% CI, 26.9 to 39.4) in the palbociclib group and 24.8% (95% CI, 19.3 to 30.0) in the standard-therapy group.

The median duration of confirmed response was 44.9 months (95% CI, 27.1 to 51.6) in the palbociclib group and 30.8 months (95% CI, 26.0 to not evaluable due to a low number of events) in the standard-therapy group.

A greater percentage of patients in the palbociclib group achieved a complete response: 14.3% versus 11.3%. This held true regardless of how patients had responded to induction therapy.

Clinical benefit was seen in 88.9% (95% CI, 84.4 to 92.4) of the palbociclib group and 80.9% (95% CI, 75.6 to 85.6) of the standard-therapy group.

At the data cutoff, 123 patients had died: 60 in the palbociclib group and 63 in the standard-therapy group. This produced a hazard ratio for death of 0.86 (95% CI, 0.61 to 1.23). Because the confidence interval crosses 1.0, this survival difference is not statistically conclusive — the data are not yet mature. According to the protocol, the final overall survival analysis will occur after 247 deaths are reported.

Key Findings: Side Effects

A total of 509 patients were included in the safety population: 261 in the palbociclib group and 248 in the standard-therapy group. Nine patients were excluded from the standard-therapy group — 8 withdrew consent before starting treatment, and 1 never received any treatment.

Adverse events of any grade occurred in every patient in the palbociclib group (100%) and in 94.4% of the standard-therapy group. The key difference was in severity.

Grade 3 adverse events — serious enough to require medical intervention but not immediately life-threatening — were more than twice as frequent with palbociclib: 79.7% versus 30.6%. This difference was driven mainly by neutropenia (dangerously low levels of neutrophils, a type of white blood cell that fights infection): 55.9% versus 2.0% — and leukopenia (low overall white blood cell count): 15.7% versus 0.8%.

Grade 4 adverse events — life-threatening and requiring urgent intervention — occurred in 10.0% of patients in the palbociclib group and 3.6% in the standard-therapy group.

Detailed breakdown of neutropenia:

• Grade 2: 14.6% with palbociclib versus 3.6% with standard therapy
• Grade 3: 55.9% versus 2.0%
• Grade 4: 4.6% versus 0%

Two patients in the palbociclib group developed febrile neutropenia — a fever combined with low neutrophils, which is a medical emergency.

Fatigue of grade 2 or higher was more frequent with palbociclib: grade 2 in 22.2% versus 12.9%, and grade 3 in 5.0% versus 0%.

Diarrhea was also more common with palbociclib: grade 2 in 27.6% versus 10.9%, and grade 3 in 9.6% versus 1.2%. The median time until onset of grade 2 or 3 diarrhea was 2.3 months in the palbociclib group. Notably, among patients who developed grade 3 diarrhea at any point in the palbociclib group, 30.8% had diarrhea recorded as a baseline symptom before the trial began.

Stomatitis (mouth sores and inflammation) of grade 2 or 3 occurred in 9.9% of patients in the palbociclib group and 0.4% of the standard-therapy group.

Grade 5 adverse events — fatal events attributed to causes other than the trial treatment — occurred in 3.8% of the palbociclib group and 4.4% of the standard-therapy group. No deaths were determined by the investigator to be related to a trial treatment. Serious adverse events occurred in 28.7% of patients receiving palbociclib and 21.8% receiving standard therapy.

Dose reductions were common. The palbociclib dose was reduced in 57.7% of patients — once in 27.7% of treated patients and twice in 30.0%. The median time until the first dose reduction was 3.2 months. Neutropenia was the most common adverse event leading to a dose reduction, occurring in 72.3% of those who had a reduction.

Adverse events led to discontinuation of palbociclib in 18.0% of patients. The most common reason was uncomplicated neutropenia — low white blood cell counts without accompanying fever or infection.

Clinical Implications: What This Means for Patients

For patients with hormone-receptor–positive, HER2-positive advanced breast cancer who have finished induction chemotherapy without their cancer worsening, adding palbociclib to maintenance therapy meaningfully delays the return of disease. The median gain was about 15 months — from 29.1 months to 44.3 months.

The benefit held at every time point measured. At two years, 65.2% of patients on palbociclib had not progressed, compared with 55.3% on standard therapy. At four years, those figures were 46.5% and 38.3%. In other words, about 10 out of every 100 patients treated were still progression-free at two years who would not have been on standard therapy alone.

More patients also achieved a deep response. Complete responses were more frequent with palbociclib (14.3% versus 11.3%), and the median duration of response was longer (44.9 months versus 30.8 months). These findings support the underlying biology: blocking HER2, the estrogen receptor, and CDK4/6 at the same time appears to overcome some of the resistance that emerges when only one or two pathways are targeted.

The trade-off is tolerability. Nearly 80% of patients on palbociclib experienced a grade 3 adverse event, compared with about 31% on standard therapy. Most of that difference was neutropenia, which occurred at grade 3 in 55.9% of palbociclib-treated patients versus 2.0% of those on standard therapy. This is important because patients need frequent blood tests. More than half of patients required a dose reduction (57.7%), and 18.0% stopped palbociclib because of side effects.

Reassuringly, no deaths were attributed to the trial treatment. Fatal events from other causes were actually slightly less common in the palbociclib group (3.8% versus 4.4%). Growth factor support was not permitted in this trial, which may have made neutropenia more prominent than it would be in routine practice — a point patients should discuss with their oncologists.

Limitations: What the Study Could Not Prove

The most significant limitation is that overall survival data are not yet mature. With 123 deaths so far, the hazard ratio for death was 0.86 (95% CI, 0.61 to 1.23). Because this confidence interval includes 1.0, the study cannot yet say whether palbociclib extends life. The final analysis is planned after 247 deaths.

Second, the trial was open-label, meaning patients and doctors knew who received palbociclib. This design can influence how symptoms are reported and how progression is assessed, though researchers used standardized RECIST criteria to reduce this risk.

Third, subgroup analyses were underpowered. The study was not large enough to determine which specific patient groups benefit most — for example, whether premenopausal patients do as well as postmenopausal patients, or whether visceral disease responds differently from nonvisceral disease.

Fourth, no statistical adjustments were made for multiple comparisons on secondary end points. This means the confidence intervals for response rates, clinical benefit, and other secondary outcomes should be interpreted carefully rather than as definitive proof.

Fifth, Black patients were underrepresented (2.9% of the trial population) and unevenly distributed between the two groups. Most participants were White (77.4% of those with race data, with 15.6% missing race information). This limits how confidently the results can be generalized to all populations.

Finally, about 10% of screened patients were found ineligible, including some whose disease had progressed after induction therapy. The exact number due to progression was not recorded. This means the enrolled population may not reflect every patient seen in real-world practice.

Recommendations and Practical Advice

If you or someone you care for has hormone-receptor–positive, HER2-positive advanced breast cancer, here are practical points to discuss with an oncology team:

1. Ask whether you are a candidate. In this trial, patients qualified after completing four to eight cycles of trastuzumab-based induction chemotherapy without disease progression, and starting the new therapy within 12 weeks of the last induction infusion.
2. Expect more frequent blood tests. Neutropenia was the dominant side effect. Complete blood counts were checked at baseline, on day 1 of cycles 1 through 4, and every 3 months afterward, with an extra check on day 22 of cycle 1.
3. Know that dose reductions are common and expected. More than half of patients needed a lower palbociclib dose, usually within about 3.2 months. Reductions were from 125 mg to 100 mg to 75 mg. This is a planned part of treatment, not a sign of failure.
4. Report fever immediately. Two patients developed febrile neutropenia, which requires urgent care. Any fever while on palbociclib should prompt a call to your care team right away.
5. Watch for diarrhea and mouth sores. Diarrhea typically began around 2.3 months into treatment. Stomatitis affected about 1 in 10 patients on palbociclib. Both are manageable when reported early.
6. Discuss growth factor support. It was not allowed in this trial, but your care team may consider it in routine practice depending on your blood counts.
7. Understand the survival question remains open. Ask your oncologist how they weigh the progression-free survival benefit against the side effect burden, and whether newer data have changed their recommendation.

The bottom line: adding palbociclib to maintenance therapy is a real, measurable advance for this specific subgroup of patients. It delays progression by roughly 15 months at the median. But it also brings frequent low blood cell counts and a high rate of dose reductions. The decision is a balance between delaying cancer growth and managing treatment side effects — one best made with a full picture of your individual health and priorities.

Frequently Asked Questions

Who was eligible to join the PATINA trial?

Eligible patients were adults with hormone-receptor–positive, HER2-positive advanced breast cancer who had completed four to eight cycles of trastuzumab-based induction chemotherapy without disease worsening. They could not have received other systemic therapy for metastatic disease, and treatment had to start within 12 weeks of the last induction infusion. Asymptomatic central nervous system metastases were allowed under certain conditions.

What did adding palbociclib to maintenance therapy achieve?

In the PATINA trial, adding palbociclib to standard maintenance therapy extended the median time before disease worsened from 29.1 months to 44.3 months. That is a 25% relative reduction in the risk of progression or death. The benefit was seen at every time point measured, but overall survival data are not yet mature, so it is not known whether palbociclib extends life.

What side effects did patients experience with palbociclib?

The main side effect was neutropenia, or low white blood cell counts. Severe neutropenia occurred in 55.9% of patients on palbociclib versus 2.0% on standard therapy. Other common side effects included fatigue, diarrhea, and mouth sores. More than half of patients needed a dose reduction, and 18% stopped palbociclib because of side effects. No deaths were attributed to the trial treatment.

How often are blood tests needed during palbociclib treatment?

In the trial, complete blood counts were checked at baseline, on day 1 of cycles 1 through 4, and every 3 months afterward. Patients in the palbociclib group had an extra blood count on day 22 of cycle 1. Because neutropenia was common, frequent monitoring is important. Your care team will decide the exact schedule for you.

What does a median progression-free survival of 44.3 months mean?

Median progression-free survival is the time at which half the patients in a group have seen their cancer grow or have died. In the PATINA trial, that time was 44.3 months with palbociclib and 29.1 months with standard therapy. It does not predict what will happen to any one person, but it shows the treatment delayed progression for many patients.

Can the palbociclib dose be reduced if side effects occur?

Yes. In the trial, dose reductions were common and expected. More than half of patients needed a lower dose, usually within about 3.2 months. Reductions went from 125 mg to 100 mg to 75 mg. If a reduction below 75 mg was needed, palbociclib was stopped permanently. Dose reduction is a planned part of managing side effects, not a sign of failure.

Does palbociclib improve overall survival?

That is not yet known. At the time of the analysis, 123 patients had died, and the hazard ratio for death was 0.86 with a confidence interval that crossed 1.0, meaning the result is not statistically conclusive. The trial continues to follow patients, and the final overall survival analysis is planned after 247 deaths are reported.

I have hormone-receptor-positive, HER2-positive advanced breast cancer and finished induction chemo without progression — should I get a second opinion before adding palbociclib to maintenance therapy?

This is a reasonable decision to review with another expert. Adding palbociclib extended median progression-free survival from 29.1 to 44.3 months, but 55.9% of treated patients had grade 3 neutropenia, 57.7% needed a dose reduction, and 18.0% stopped the drug for side effects. Overall survival data are not yet mature. A second opinion can help weigh that progression-free benefit against the side-effect burden and confirm whether you meet the trial's eligibility criteria. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer

Authors: O. Metzger, S. Mandrekar, S. Goel, J. Gligorov, E. Lim, E. Ciruelos, S. Loibl, T. Dockter, X. Gonzàlez Farré, P.A. Francis, F. Lynce, J. Lanzillotti, C. DuFrane, A. Wall, C. Strand, I. Krop, I. Vaz-Luis, D. Tripathy, S. Loi, A. Prat, M. Goetz, S. Escrivá-de-Romaní, D. Porter, J. Spoenlein, D.G. Stover, S. Sardesai, P. Heudel, M. Koehler, C. Huang Bartlett, A. Holynskyj, P. Gopalakrishna, E. Gauthier, S. Delaloge, K. Miller, E.P. Winer, L. Gianni, A.H. Partridge, A. DeMichele, and L.A. Carey

Publication: New England Journal of Medicine, 2026;394:451-462. Article updated March 27, 2026. DOI: 10.1056/NEJMoa2511218. Copyright © 2026 Massachusetts Medical Society.

Trial registration: PATINA, ClinicalTrials.gov number NCT02947685.

Funding: Pfizer and others (academic collaboration led by Alliance Foundation Trials in partnership with Breast Cancer Trials, Fondazione Michelangelo, GBG Forschungs, PrECOG Cancer Research Group, SOLTI Breast Cancer Research Group, and Unicancer).

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace personalized medical advice. Please discuss your individual treatment options with your oncology team.